TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10865321

Group type: EXPERIMENTAL
Intervention: Visual acuity worse than 20/40 in the 65-74 age group
Number of subjects: 3821

Group type: EXPERIMENTAL
Intervention: Visual acuity worse than 20/40 in the 80-84 age group
Number of subjects: 3821

Group type: EXPERIMENTAL
Intervention: Refraction intervention
Number of subjects: 3821

Group type: EXPERIMENTAL
Intervention: Best-corrected acuity worse than 20/40
Number of subjects: 3821

Group type: EXPERIMENTAL
Intervention: Visual impairment among African Americans
Number of subjects: 3821

Group type: EXPERIMENTAL
Intervention: Causes of impairment and blindness
Number of subjects: 3821
Study: 9354111

Group type: EXPERIMENTAL
Intervention: Right nostril breathing
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Left nostril breathing
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Alternate nostril breathing
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Breath awareness without manipulation of nostrils
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (age-matched, N = 27)
Number of subjects: 108
Study: 7692110

Group type: EXPERIMENTAL
Intervention: 1 mg finasteride
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 5 mg finasteride
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 3816290

Group type: EXPERIMENTAL
Intervention: Merieux rubella vaccine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Wellcome RA27/3 rubella vaccine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low pre-vaccine titre subjects
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High pre-vaccine titre subjects
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both vaccines
Number of subjects: 100
Study: 29808324

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO), treated once daily at a pressure of 2.0 atm absolute with 100% oxygen.
Number of subjects: 73

Group type: COMPARATOR
Intervention: No hyperbaric oxygen therapy (no-HBO), standard arm.
Number of subjects: 73
Study: 26679552

Group type: EXPERIMENTAL
Intervention: Ultrasonic resorbable pin fixation (URPF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 10
Study: 24800227

Group type: EXPERIMENTAL
Intervention: Minimally invasive video-assisted thyroidectomy (MIVAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimally invasive nonendoscopic thyroidectomy (MINET)
Number of subjects: 0
Study: 22119930

Group type: EXPERIMENTAL
Intervention: G-CSF (5 μg/kg subcutaneously, 12 doses)
Number of subjects: 47
Study: 20124207

Group type: EXPERIMENTAL
Intervention: Pregabalin (average daily dosage 385.7 mg/d)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 302
Study: 17593563

Group type: EXPERIMENTAL
Intervention: Violent video game play
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 16202888

Group type: EXPERIMENTAL
Intervention: 12 mg/kg/d zoniporide
Number of subjects: 824

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 824
Study: 12134176

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs) treatment for 6 months in group A
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs) treatment for 1 year in group B
Number of subjects: 81
Study: 10201661

Group type: EXPERIMENTAL
Intervention: Ropivacaine (n = 34)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Bupivacaine (n = 39)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Ropivacaine
Number of subjects: 73

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 73
Study: 7539873

Group type: EXPERIMENTAL
Intervention: Chemotherapy (cisplatin 20 mg/m2 day 1-5, bleomycin 10 mg/m2 continuous infusion from day 3-7, methotrexate 40 mg/m2 on day 15 and day 22, repeated on day 29 for two cycles)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard treatment (surgery + radiation)
Number of subjects: 54
Study: 2178412

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 7004254

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 0
Study: 31063479

Group type: EXPERIMENTAL
Intervention: Spanish version of the Düsseldorfer Ortorexie Skala (DOS)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Exploratory factor analysis
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Confirmatory factor analysis
Number of subjects: 492
Study: 27033346

Group type: EXPERIMENTAL
Intervention: ToyBox-intervention (1-year intervention including physical activity sessions, classroom activities, environmental changes, and tools for parents)
Number of subjects: 1293

Group type: EXPERIMENTAL
Intervention: ToyBox-intervention
Number of subjects: 1293
Study: 25725181

Group type: EXPERIMENTAL
Intervention: Propofol‐atracurium
Number of subjects: 224

Group type: COMPARATOR
Intervention: Thiopental‐atracurium
Number of subjects: 224
Study: 23504678

Group type: COMPARATOR
Intervention: General anesthesia (group 1)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (group 2)
Number of subjects: 110
Study: 20679501

Group type: EXPERIMENTAL
Intervention: Single 150 mg dose of caspofungin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Single 210 mg dose of caspofungin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Multiple 100 mg doses of caspofungin for 21 days
Number of subjects: 36
Study: 19729951

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) for 6 months
Number of subjects: 26
Study: 17241413

Group type: EXPERIMENTAL
Intervention: BoNTA(2) (Dysport, Ipsen Ltd.) at dose ratios of 1:2.5, 1:3, or 1:4
Number of subjects: 20

Group type: COMPARATOR
Intervention: BoNTA(1) (BOTOX, Allergan, Inc.)
Number of subjects: 20
Study: 15078741

Group type: EXPERIMENTAL
Intervention: Nimesulide, 100 mg orally twice daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ibuprofen, 400 mg orally three times daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no NSAIDs)
Number of subjects: 30
Study: 11192875

Group type: EXPERIMENTAL
Intervention: SOUNDTEC Direct Drive Hearing System (DDHS)
Number of subjects: 10
Study: 9252814

Group type: EXPERIMENTAL
Intervention: Intermittent impulse compression
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continuous cryotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard therapy (cool packs)
Number of subjects: 60
Study: 8510986

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3604971

Group type: EXPERIMENTAL
Intervention: 1:1 mixture of xanthan and locust bean gum (X/LBG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guar gum, xanthan, locust-bean gum
Number of subjects: 0
Study: 31648661

Group type: EXPERIMENTAL
Intervention: Consanguineous marriages
Number of subjects: 5255

Group type: EXPERIMENTAL
Intervention: Arranged marriages
Number of subjects: 5255

Group type: EXPERIMENTAL
Intervention: Parental consanguinity in patients with β-thalassaemia
Number of subjects: 5255
Study: 27575546

Group type: EXPERIMENTAL
Intervention: 10 mg RAD1901 daily for 28 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 25 mg RAD1901 daily for 28 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 50 mg RAD1901 daily for 28 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 100 mg RAD1901 daily for 28 days
Number of subjects: 100
Study: 25769196

Group type: EXPERIMENTAL
Intervention: Lateral approach
Number of subjects: 216

Group type: COMPARATOR
Intervention: Posterior approach
Number of subjects: 216
Study: 24223362

Group type: EXPERIMENTAL
Intervention: Acetaminophen plus honey
Number of subjects: 104

Group type: COMPARATOR
Intervention: Acetaminophen plus placebo
Number of subjects: 104
Study: 21297561

Group type: COMPARATOR
Intervention: Single-trial line drill test (SLDT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single-trial line drill test (SLDT) in basketball players (BP)
Number of subjects: 24
Study: 19789532

Group type: EXPERIMENTAL
Intervention: Bevacizumab with first-line chemotherapy
Number of subjects: 1914

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1914

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1914
Study: 16931172

Group type: EXPERIMENTAL
Intervention: Kcanrenoate (100 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 15063399

Group type: EXPERIMENTAL
Intervention: Folic acid fortification (1998)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation for 10 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Baseline measurements (1997)
Number of subjects: 18
Study: 11560098

Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinyl estradiol plus 125 micrograms levonorgestrel
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 20 micrograms ethinyl estradiol plus 150 micrograms desogestrel
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control cycle (early follicular phase)
Number of subjects: 13
Study: 9624787

Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate 50 micrograms twice daily via the Diskus inhaler
Number of subjects: 263

Group type: COMPARATOR
Intervention: Terbutaline sulphate 500 micrograms four times daily via the Turbuhaler inhaler
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Diskus inhaler
Number of subjects: 263

Group type: COMPARATOR
Intervention: Turbuhaler inhaler
Number of subjects: 263
Study: 7825420

Group type: EXPERIMENTAL
Intervention: Fotil (0.5% timolol and 2% pilocarpine)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Timpilo (0.5% timolol and 2% pilocarpine)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Both Fotil and Timpilo
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Fotil
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Timpilo
Number of subjects: 89
Study: 3135698

Group type: EXPERIMENTAL
Intervention: Vented group (4.5 mm lateral drill hole 4 cm distal the tip of the prosthesis)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no venting hole)
Number of subjects: 26
Study: 31599479

Group type: EXPERIMENTAL
Intervention: AVB‐S6‐500 at a dose of 1 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AVB‐S6‐500 at a dose of 5 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AVB‐S6‐500 at a dose of 10 mg/kg
Number of subjects: 0
Study: 30672256

Group type: EXPERIMENTAL
Intervention: shu-deep needling and bloodletting technique
Number of subjects: 70

Group type: COMPARATOR
Intervention: regular needling technique (even-needling technique)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 28780718

Group type: EXPERIMENTAL
Intervention: Biodentine®
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate
Number of subjects: 51

Group type: COMPARATOR
Intervention: Formocresol (Control)
Number of subjects: 51
Study: 26887115

Group type: EXPERIMENTAL
Intervention: Yagel-Detox
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 24600731

Group type: EXPERIMENTAL
Intervention: Devil's claw root
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21922934

Group type: EXPERIMENTAL
Intervention: Blended essential oil (lavender and bergamot) applied topically to the skin of the abdomen
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Blended essential oil (lavender and bergamot)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study: 19214928

Group type: EXPERIMENTAL
Intervention: Steroids given acutely for Bell's palsy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiviral therapy for Ramsay Hunt syndrome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiviral therapy for severe cases of Bell's palsy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotics for Lyme facial neuropathy
Number of subjects: 0
Study: 16749407

Group type: EXPERIMENTAL
Intervention: 10 mg barnidipine
Number of subjects: 85

Group type: COMPARATOR
Intervention: 10 mg benazepril
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control (benazepril)
Number of subjects: 85
Study: 14715881

Group type: EXPERIMENTAL
Intervention: Recombinant human IGF‐I
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant human GH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11758305

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 60
Study: 9272538

Group type: EXPERIMENTAL
Intervention: Cardioversion with subsequent antiarrhythmic drug therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control of the ventricular rate during persistent atrial fibrillation
Number of subjects: 0
Study: 8204701

Group type: EXPERIMENTAL
Intervention: Regimen GL (glucose-lipid-based TPN)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Regimen G (glucose-based TPN)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 17
Study: 3335727

Group type: EXPERIMENTAL
Intervention: 45 minutes of exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study: 31668693

Group type: EXPERIMENTAL
Intervention: Anticholinergic drug scale (ADS) score assessment
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Age (per year)
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: ASA state
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: ICU stay (yes vs. no)
Number of subjects: 651
Study: 30204916

Group type: EXPERIMENTAL
Intervention: Standard ECD program with additional activities to improve nutritious food production and behavior change communication
Number of subjects: 1552

Group type: COMPARATOR
Intervention: Save the Children's ECD program
Number of subjects: 1552
Study: 28805611

Group type: EXPERIMENTAL
Intervention: Short I-D interval (1 mg/kg propofol and 1 μg/kg remifentanil; maintained by continuous infusion of 3 mg/kg/h propofol and 7 μg/kg/h remifentanil)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Long I-D interval (1 mg/kg propofol and 1 μg/kg remifentanil; maintained by continuous infusion of 3 mg/kg/h propofol and 7 μg/kg/h remifentanil)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups (short and long I-D intervals)
Number of subjects: 40
Study: 25664962

Group type: EXPERIMENTAL
Intervention: Combination of Pycnogenol®, roburins, L‐arginine, L‐citrulline
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23959152

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 581

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 581
Study: 21352880

Group type: EXPERIMENTAL
Intervention: Netball exercise
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sedentary period
Number of subjects: 11
Study: 18680235

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily)
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1024
Study: 22682553

Group type: COMPARATOR
Intervention: Abciximab with unfractionated heparin (UFH)
Number of subjects: 564

Group type: COMPARATOR
Intervention: Bivalirudin
Number of subjects: 564
Study: 15799844

Group type: EXPERIMENTAL
Intervention: OCA group (omeprazole 20 mg bid, clarithromycin 500 mg bid, amoxicillin 1000 mg bid)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: OCA group
Number of subjects: 158

Group type: COMPARATOR
Intervention: OCA group vs Placebo group
Number of subjects: 158
Study: 12797399

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) with BCNU
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Bio-chemotherapy (Bio-CT) with BCNU
Number of subjects: 176

Group type: COMPARATOR
Intervention: Chemotherapy (CT) without BCNU
Number of subjects: 176

Group type: COMPARATOR
Intervention: Bio-chemotherapy (Bio-CT) without BCNU
Number of subjects: 176
Study: 10760840

Group type: EXPERIMENTAL
Intervention: Deramciclane (0.2 to 50 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Deramciclane (50 to 150 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: N-desmethyl deramciclane (active metabolite)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Deramciclane (all doses)
Number of subjects: 32
Study: 7781752

Group type: EXPERIMENTAL
Intervention: regramostim
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: molgramostim
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: sargramostim
Number of subjects: 69
Study: 2194264

Group type: EXPERIMENTAL
Intervention: Experimental therapy (specifics not provided)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Conventional two-sample tests (t and rank-sum)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: O'Brien tests
Number of subjects: 230
Study: 619948

Group type: EXPERIMENTAL
Intervention: Motival (fluphenazine 0.5 mg and nortriptyline 10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diazepam 7.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Motival
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Propranolol 60 mg
Number of subjects: 12
Study: 11929322

Group type: EXPERIMENTAL
Intervention: 6 mg oral dose of rivastigmine
Number of subjects: 11

Group type: COMPARATOR
Intervention: 2 mg intravenous dose of rivastigmine
Number of subjects: 11
Study: 31005287

Group type: EXPERIMENTAL
Intervention: Oxaliplatin-capecitabine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Paclitaxel-carboplatin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oxaliplatin-capecitabine-bevacizumab
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Paclitaxel-carboplatin-bevacizumab
Number of subjects: 50
Study: 30123399

Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 26832963

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg loading dose and then 20 mg daily until the earliest of 3 days after discharge from intensive care, study day 28, or death)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 272
Study: 24917661

Group type: EXPERIMENTAL
Intervention: Single-dose metronidazole (2 grams)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Multidose metronidazole (500 mg twice daily for 7 days)
Number of subjects: 226

Group type: COMPARATOR
Intervention: ART users
Number of subjects: 226

Group type: COMPARATOR
Intervention: Non-ART users
Number of subjects: 226
Study: 22188832

Group type: EXPERIMENTAL
Intervention: HPV + HAB
Number of subjects: 813

Group type: COMPARATOR
Intervention: HAB
Number of subjects: 813

Group type: COMPARATOR
Intervention: HPV
Number of subjects: 813
Study: 20151965

Group type: EXPERIMENTAL
Intervention: Early nephrostomy removal
Number of subjects: 22

Group type: COMPARATOR
Intervention: Tubeless PCNL
Number of subjects: 22
Study: 18723319

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (DSE) with Tissue Doppler imaging (TDI)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (age- and gender-matched)
Number of subjects: 21
Study: 15939560

Group type: EXPERIMENTAL
Intervention: Continuous combined hormonal therapy (conjugated equine estrogens 0.625 mg/die plus medroxyprogesterone acetate 5 mg/die)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/die
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 103
Study: 12826986

Group type: EXPERIMENTAL
Intervention: Pregabalin 200 mg tid
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg tid
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Pregabalin 50 mg tid
Number of subjects: 271
Study: 10767486

Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine
Number of subjects: 100
Study: 10895803

Group type: EXPERIMENTAL
Intervention: imipramine/propantheline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: oxybutynin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: penthienate
Number of subjects: 0
Study: 1513117

Group type: EXPERIMENTAL
Intervention: Cool temperature dialysis (CTD)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Regular temperature dialysis (RTD)
Number of subjects: 6
Study: 6360431

Group type: EXPERIMENTAL
Intervention: Fenfluramine (60 mg, orally)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30577724

Group type: EXPERIMENTAL
Intervention: Lecture on oral health education (OHE) given by dentists
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Lecture on oral health education (OHE) given by school teachers
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1053
Study: 30323581

Group type: EXPERIMENTAL
Intervention: YuPingFeng granules (5 g, three times per day for 1 year)
Number of subjects: 240
Study: 27068773

Group type: EXPERIMENTAL
Intervention: Systematic, theory informed intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-participating GPs (locum/part-time GPs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participating GPs
Number of subjects: 0
Study: 24442243

Group type: EXPERIMENTAL
Intervention: Real-time visual feedback (IG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Verbal information from a physiotherapist (CG)
Number of subjects: 20
Study: 23208837

Group type: EXPERIMENTAL
Intervention: Workshop with standardised teaching material and role playing
Number of subjects: 694

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 694